Biosynex (ALBIO)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 0.790 |
|---|---|
| 52-week range | 0.455 – 1.570 |
| Return, 1 month / 3 months | −13.0% / −15.2% |
| Return, 1 year / 3 years | +16.9% / −89.1% |
| Trend | Below its 200-day average |
| RSI (14) | 38 |
| Volatility (1 year) | 85.7% |
| Worst drawdown (1 year) | -50.1% |
| Average daily value traded | 0.02M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Biosynex is a French diagnostics company based in Strasbourg that designs and makes rapid medical tests. Its products include lateral flow tests for infectious diseases, fertility and pregnancy, along with self-tests and point-of-care devices. Customers are mainly pharmacies, healthcare professionals and laboratories, and the company also supplies tests for veterinary and food safety uses. It develops its own technology and manufactures tests for sale in France and other markets.
On this site Biosynex appears as a stock on the Euronext Paris (France), code ALBIO, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Biosynex (ALBIO) trades on the Euronext Paris in France. It last closed at EUR 0.790 on 23 October 2026.
Its price-based Market X-Ray is 42 out of 100 (a weak price profile), ranking 419 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 16.9% and over the last three months it fell 15.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 39 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -13.1% | ||
| From 52-week high | -49.7% | ||
| Momentum | 62 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -15.2% | ||
| 6-month return | -5.3% | ||
| 12-month return, skipping the last month | 34.3% | ||
| Stability (higher is calmer) | 22 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 85.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -50.1% | ||
| Liquidity | 47 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −6.0% |
|---|---|
| 1 month | −13.0% |
| 3 months | −15.2% |
| 6 months | −5.3% |
| 1 year | +16.9% |
| 3 years | −89.1% |
| 5 years | −93.2% |
Signals
| 50-day / 200-day average | 0.887 / 0.909 |
|---|---|
| Golden / death cross (60 days) | Death, 6 days ago |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.062 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 16 May 2022 | EUR 2.0000 |
| 26 May 2021 | EUR 0.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.